Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer
- PMID: 28529650
- PMCID: PMC5436526
- DOI: 10.7150/thno.18421
Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer
Abstract
Background: By targeting the prostate-specific membrane antigen (PSMA) on prostate cancer (PCa) cells PSMA-PET/CT shows great potential in locating the site of biochemical recurrence even at low PSA (Prostate-specific antigen)-levels. Accurate imaging of PCa recurrent lymph node metastases (LNM) is crucial for metastases directed therapies such as salvage-lymph node dissection (salvage-LND). Objective: To evaluate the diagnostic accuracy of PSMA-PET/CT for detection of affected lymph-node regions at salvage-LND for nodal recurrence of PCa. Design, setting and participants: 30 patients with the suspicion of exclusively nodal PCa-relapse after primary therapy underwent a template pelvic and/or retroperitoneal salvage-LND after whole body 68-Ga-PSMA-PET/CT. The diagnostic accuracy of PET/CT was evaluated in comparison to the histopathology of 965 resected lymph nodes (LN) dissected from 68 main regions (pelvic left/right, retroperitoneal) and 289 subregions (common iliac, external iliac, obturator, internal iliac, presacral, aortic-bifurcation, aortal, caval). LNM and tumor deposits in LNM were measured bidimensionally in the histopathology. PSMA-expression was analyzed by immunohistochemistry in LNM. Results: LNM were present in 11.4% of the resected LN (110/965) resulting in 45 positive main regions and 85 positive subregions. PET/CT was true positive in 41 main regions and 69 subregions. Three PET-negative main regions and 16 PET-negative subregions finally contained LNM, the majority of these false negative subregions (13/16) were in neighboring regions of true-positive subregions. Sensitivity, specificity, positive predictive value, negative predictive value and accuracy were: main region-based 93.2%, 100%, 100%, 88.9% and 95.6%, subregion-based 81.2%, 99.5%, 98.6%, 92.7 and 94.1%. Median short diameters of tumor deposits in LNM resected from false-negative subregions (1.3 mm) were significantly smaller than in LNM removed from true-positive subregions (5.5 mm, p<0.0001). Based on anatomical subregions containing just one LNM, the necessary short diameter of tumor deposits in LNM required to reach a detection rate of 50% and 90% was estimated to be ≥ 2.3 mm and ≥ 4.5 mm, respectively. Conclusion: In men with biochemical PCa-relapse and positive PSMA-PET/CT, PET/CT detects metastatic affected anatomical regions with high accuracy at a main region and at a subregion-level. If the decision for salvage-LND is prompted by a positive PSMA-PET/CT, the size of metastases is crucial for accurate detection of affected regions. All LNM showed a clear PSMA-expression in the immunohistochemistry. Further studies need to investigate how to translate the high anatomical correlation observed between PET/CT and surgical findings into optimal approaches for target salvage-LND.
Keywords: PSMA-PET/CT; prostate cancer, lymph node metastases; salvage lymph node dissection; salvage lymphadenectomy..
Conflict of interest statement
Competing Interests: PTM received financial support for on-going research by GE and Piramal Imaging unrelated to the present study. CAJ, VD, TB, KS, WSS, UW, HCR, WV have no financial disclosures.
Figures





Comment in
-
Re: Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-ligand-PET/CT Before Salvage Lymph Node Dissection for Recurrent Prostate Cancer.Eur Urol. 2017 Sep;72(3):470-471. doi: 10.1016/j.eururo.2017.05.007. Epub 2017 May 15. Eur Urol. 2017. PMID: 28522176 No abstract available.
-
PSMA-PET for Lymph Node Detection in Recurrent Prostate Cancer: How do we use the Magic Bullet?Theranostics. 2017 May 15;7(7):2046-2047. doi: 10.7150/thno.20855. eCollection 2017. Theranostics. 2017. PMID: 28638485 Free PMC article. No abstract available.
Similar articles
-
Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy.J Nucl Med. 2016 Nov;57(11):1713-1719. doi: 10.2967/jnumed.116.173492. Epub 2016 Jun 3. J Nucl Med. 2016. PMID: 27261524
-
Detection Rate of 18F-Choline PET/CT and 68Ga-PSMA-HBED-CC PET/CT for Prostate Cancer Lymph Node Metastases with Direct Link from PET to Histopathology: Dependence on the Size of Tumor Deposits in Lymph Nodes.J Nucl Med. 2019 Jul;60(7):971-977. doi: 10.2967/jnumed.118.220541. Epub 2019 Jan 25. J Nucl Med. 2019. PMID: 30683768 Free PMC article.
-
68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer.Eur Urol. 2016 Oct;70(4):553-557. doi: 10.1016/j.eururo.2015.12.051. Epub 2016 Jan 19. Eur Urol. 2016. PMID: 26810345
-
68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.Eur Urol Focus. 2018 Sep;4(5):686-693. doi: 10.1016/j.euf.2016.11.002. Epub 2016 Nov 15. Eur Urol Focus. 2018. PMID: 28753806
-
Prostate-specific membrane antigen-guided salvage lymph node dissection in recurrent prostate cancer: a novel technology to detect lymph node metastases.Curr Opin Urol. 2018 Mar;28(2):191-196. doi: 10.1097/MOU.0000000000000458. Curr Opin Urol. 2018. PMID: 29028767 Review.
Cited by
-
Performance of 111In-labelled PSMA ligand in patients with nodal metastatic prostate cancer: correlation between tracer uptake and histopathology from lymphadenectomy.Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2062-2070. doi: 10.1007/s00259-018-4094-0. Epub 2018 Jul 30. Eur J Nucl Med Mol Imaging. 2018. PMID: 30062606
-
[Metachronous oligometastatic prostate cancer-the more the better or only local treatment?].Urologe A. 2021 Dec;60(12):1534-1545. doi: 10.1007/s00120-021-01701-7. Epub 2021 Nov 3. Urologe A. 2021. PMID: 34734294 Review. German.
-
Outcome after PSMA PET/CT based salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy: a bi-institutional retrospective analysis.J Nucl Med. 2019 Feb 1;60(2):227-233. doi: 10.2967/jnumed.118.212563. Epub 2018 Jul 12. J Nucl Med. 2019. PMID: 30002108 Free PMC article.
-
99mTc-labelled PSMA ligand for radio-guided surgery in nodal metastatic prostate cancer: proof of principle.EJNMMI Res. 2021 Mar 4;11(1):22. doi: 10.1186/s13550-021-00762-1. EJNMMI Res. 2021. PMID: 33661414 Free PMC article.
-
Prostate specific membrane antigen (PSMA) and Prostate Cancer Staging: is our current conventional staging obsolete?Int Braz J Urol. 2021 Nov-Dec;47(6):1243-1249. doi: 10.1590/S1677-5538.IBJU.2020.0997. Int Braz J Urol. 2021. PMID: 33861056 Free PMC article. No abstract available.
References
-
- Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T. et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. European urology. 2014;65:467–79. - PubMed
-
- Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T. et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. European urology. 2014;65:124–37. - PubMed
-
- Picchio M, Briganti A, Fanti S, Heidenreich A, Krause BJ, Messa C. et al. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. European urology. 2011;59:51–60. - PubMed
-
- Jilg CA, Schultze-Seemann W, Drendel V, Vach W, Wieser G, Krauss T, Detection of Lymph Node Metastasis in Patients with Nodal Prostate Cancer Relapse Using F/C-Choline Positron Emission Tomography/Computerized Tomography. The Journal of urology; 2014. - PubMed
-
- Cimitan M, Evangelista L, Hodolic M, Mariani G, Baseric T, Bodanza V. et al. Gleason score at diagnosis predicts the rate of detection of 18F-choline PET/CT performed when biochemical evidence indicates recurrence of prostate cancer: experience with 1,000 patients. J Nucl Med. 2015;56:209–15. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous